Detection of Prostate Cancer Using Serum Proteomics Pattern in a Histologically Confirmed Population

Li, Jinong; White, Nicole M.; Zhang, Zhen; Rosenzweig, Jason M.; Mangold, Leslie A.; Partin, Alan W.; Chan, Daniel W.

doi:10.1097/01.ju.0000119823.86393.49

Cited by 54 publications

(30 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It shows great potential to contribute to research dealing with the early detection of several cancers using serum and other biological materials [6]. This approach has been useful for identifying specific and sensitive molecular markers in patients with ovarian, liver, pancreatic and prostatic malignancies [7][8][9][10]. However, there have been no reports of proteomics technology being used to identify the unique proteins that are up-regulated during the progression of prostate cancer to an androgen-independent state.…”

Section: Introductionmentioning

confidence: 99%

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Yamamoto-Ishikawa¹,

Suzuki²,

Nezu³

et al. 2009

Asian J Androl

View full text Add to dashboard Cite

Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has been termed as hormone refractory. To identify the proteins that mediate progression to the hormone-refractory state, we used protein-chip technology for mass profiling of patients' sera. This study included 16 patients with metastatic hormone-refractory prostate cancer who were initially treated with androgen deprivation therapy. Serum samples were collected from each patient at five time points: point A, pre-treatment; point B, at the nadir of the prostatespecific antigen (PSA) level; point C, PSA failure; point D, the early hormone-refractory phase; and point E, the late hormone-refractory phase. Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed protein mass profiling of the patients' sera and identified a 6 640-Da peak that increased with disease progression. Target proteins were partially purified, and by amino acid sequencing the peak was identified as a fragment of apolipoprotein C-I (ApoC-I). Serum ApoC-I protein levels increased with disease progression. On immunohistochemical analysis, the ApoC-I protein was found localized to the cytoplasm of the hormone-refractory cancer cells. In this study, we showed an increase in serum ApoC-I protein levels in prostate cancer patients during their progression to the hormone-refractory state, which suggests that ApoC-I protein is related to progression of prostate cancer. However, as the exact role of ApoC-I in prostate cancer pathogenesis is unclear, further research is required.

show abstract

Section: Introductionmentioning

confidence: 99%

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Yamamoto-Ishikawa¹,

Suzuki²,

Nezu³

et al. 2009

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…The identities of these potential biomarkers are currently under investigation. Li et al [104], using the same proteomic method, also selected a panel of three proteins PC-1, PC-2, and PC-3 as the serum biomarkers in the early detection of prostate cancer.…”

Section: Clinical Proteomicsmentioning

confidence: 99%

Proteomics in human cancer research

Pastwa

Somiari

Czyż

et al. 2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

Proteomics is now widely employed in the study of cancer. Many laboratories are applying the rapidly emerging technologies to elucidate the underlying mechanisms associated with cancer development, progression, and severity in addition to developing drugs and identifying patients who will benefit most from molecular targeted compounds. Various proteomic approaches are now available for protein separation and identification, and for characterization of the function and structure of candidate proteins. In spite of significant challenges that still exist, proteomics has rapidly expanded to include the discovery of novel biomarkers for early detection, diagnosis and prognostication (clinical application), and for the identification of novel drug targets (pharmaceutical application). To achieve these goals, several innovative technologies including 2-D-difference gel electrophoresis, SELDI, multidimensional protein identification technology, isotope-coded affinity tag, solid-state and suspension protein array technologies, X-ray crystallography, NMR spectroscopy, and computational methods such as comparative and de novo structure prediction and molecular dynamics simulation have evolved, and are being used in different combinations. This review provides an overview of the field of proteomics and discusses the key proteomic technologies available to researchers. It also describes some of the important challenges and highlights the current pharmaceutical and clinical applications of proteomics in human cancer research.

show abstract

“…Several serum proteomic patterns for early detection of prostate cancer with high specificity and sensitivity have been described in recent years [151][152][153][154]. Other studies have revealed many peaks that could be used as biomarkers to identify prostate cancer in early stages [155][156][157][158].…”

Section: Plasma/serummentioning

confidence: 99%

A better understanding of molecular mechanisms underlying human disease

Bermúdez-Crespo

López

2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

This review summarises and discusses the degree to which proteomics is contributing to medical care, providing examples and signspots for future directions. Why do genomic approaches provide a limited view of gene expression? Because of the multifactorial nature of many diseases, proteomics enables us to understand the molecular basis of disease, not only at the organism, whole‐cell or tissue levels, but also in subcellular structures, protein complexes and biological fluids. The application of proteomics in medicine is expected to have a major impact by providing an integrated view of individual disease processes. This review describes several proteomic platforms and examines the role of proteomics as a tool for clinical biomarker discovery, the identification of prognostic and earlier diagnostic markers, their use in monitoring the effects of drug treatments and eventually find more efficient and safer therapeutics for a wide range of pathologies.

show abstract

Detection of Prostate Cancer Using Serum Proteomics Pattern in a Histologically Confirmed Population

Abstract: Serum proteomics patterns may potentially aid in the early detection of prostate cancer.

Cited by 54 publications

References 14 publications

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

Proteomics in human cancer research

A better understanding of molecular mechanisms underlying human disease

Contact Info

Product

Resources

About